26 August 2015
Vol 7, Issue 302

About The Cover

Cover image expansion

ONLINE COVER Liquid Biopsy. Circulating tumor DNA (ctDNA) can be captured from a simple, minimally invasive blood draw and then analyzed to understand a patient's disease. In this issue, Garcia-Murillas et al. show that tracking ctDNA mutations over time can tell breast cancer patients if they are at risk of relapse—some nearly 1 year before the cancer comes back—and what drugs might work best. Such early detection and prediction could change the way doctors care for their patients and plan personalized treatment regimens. See the related Focus by Sundaresan and Haber. [CREDIT: T. YURCHENKO/SHUTTERSTOCK]